Tsc1 Regulates the Proliferation Capacity of Bone-Marrow Derived Mesenchymal Stem Cells

Maria V Guijarro1,2, Laura S Danielson1, Marta Cañamero3

  • 1Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY 10016, USA.

Cells
|September 15, 2020
PubMed

Insights

Tuberous Sclerosis Complex 1 (TSC1) loss in mesenchymal stem cells (MSCs) causes overgrowth, which is reversible with mTOR inhibitors. TSC1 loss also impairs MSC differentiation and promotes senescence in aged mice.

Area of Science:

  • Cell Biology
  • Developmental Biology
  • Genetics

Background:

  • * Tuberous Sclerosis Complex 1 (TSC1) is a tumor suppressor regulating cell growth through the mammalian target of rapamycin complex 1 (mTORC1).
  • * Mutations in TSC1 cause Tuberous Sclerosis Complex (TSC), a disorder marked by benign tumors. TSC1's role in hematopoietic stem cells is known, but its function in mesenchymal stem cells (MSCs) is unclear.

Purpose of the Study:

  • * To investigate the role of Tsc1 in the biology of murine bone marrow (BM)-MSCs.
  • * To determine the impact of Tsc1 inactivation on MSC proliferation, differentiation, and potential pathologies.

Main Methods:

  • * Used tissue-specific cre-recombination (transgelin-mediated) to inactivate Tsc1 in murine BM-MSCs.
  • * Analyzed Tsc1 mutant mice for phenotypes, survival, and organ pathologies.
  • * Assessed BM-MSC proliferation in vivo and in vitro, including colony-forming potential.
  • * Treated mice with the mTOR inhibitor everolimus.
  • * Evaluated reactive oxygen species (ROS) and senescence in aged mice.
  • * Utilized ShRNA to knock down Tsc1 in BM-MSCs and assessed differentiation capacity.

Main Results:

  • * Tsc1 inactivation in BM-MSCs led to dwarfed phenotypes, TSC-like pathologies, and reduced survival.
  • * Young Tsc1-deficient mice exhibited significant BM cell expansion and increased MSC colony formation, which normalized with everolimus treatment.
  • * Aged Tsc1-deficient mice lost the hyperproliferative phenotype but showed elevated ROS and increased senescence.
  • * Tsc1 knockdown in BM-MSCs caused hyperproliferation and impaired adipogenic and myogenic differentiation.

Conclusions:

  • * Tsc1 acts as a negative regulator of BM-MSC proliferation.
  • * The Tsc1-mTOR axis plays a crucial role in maintaining the mesenchymal progenitor pool.
  • * Tsc1 deficiency impacts MSC function, leading to proliferation defects, impaired differentiation, and age-dependent senescence.

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.7K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
3.6K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
9.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.7K